All articles by Hasini Devarasetti

Hasini Devarasetti

UHN and Providence Therapeutics to develop new mRNA cancer treatments

The new mRNA-based products will be developed and manufactured in Canada.

Cytovation raises funding to clinically advance CyPep-1

The latest financing round brings total Series A funding raised by the company to over $28m.

PharmaEssentia picks Pint-Pharma to market BESREMi in Latin America

Pint-Pharma will maintain all the marketing authorisations for BESREMi in the region.

NICE recommends Bristol-Myers Squibb’s mavacamten

Approximately 7,000 people will now be able to choose this treatment for obstructive HCM on the NHS.

Open Philanthropy awards $1.7m to Evotec for henipavirus therapy discovery

Evotec’s platform helps to discover and develop suitable rSM binders that provide orally available drugs.

China’s NMPA accepts Akeso’s NDA for ebronucimab

Ebronucimab is intended to treat primary hypercholesterolemia, mixed hyperlipidemia and HeFH.

AB Science announces Canadian patent for masitinib to treat ALS

Masitinib has received orphan drug designation from the US Food and Drug Administration.

EC approves Briumvi to treat relapsing forms of multiple sclerosis

The approval comes after Briumvi was approved by the US FDA in December last year for treatment of RMS in adult patients.

Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)

The new patent expands coverage for certain ANAVEX 2-73 crystal forms preparation methods and compositions.

Swiss company Lonza acquires Synaffix to boost ADC offering

The deal amount includes an initial $107.17m cash consideration and an additional performance-based consideration of $64.3m.